Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Phenylephrine
Drug ID BADD_D01762
Description Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil,[L9413] and induce local vasoconstriction.[A187370] The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s.[A187376] Phenylephrine was granted FDA approval in 1939.[L9413]
Indications and Usage Phenylephrine injections are indicated to treat hypotension caused by shock or anesthesia,[L9416, L9410] an ophthalmic formulation is indicated to dilate pupils[L9413] and induce vasoconstriction, an intranasal formulation is used to treat congestion, and a topical formulation is used to treat hemorrhoids.[A187370] Off-label uses include situations that require local blood flow restriction such as the treatment of priapism.[A187370]
Marketing Status approved
ATC Code C01CA06; R01AA04; R01AB01; R01BA03; S01FB01; S01GA05
DrugBank ID DB00388
KEGG ID D08365
MeSH ID D010656
PubChem ID 6041
TTD Drug ID D0O6IU
NDC Product Code 57218-710
UNII 1WS297W6MV
Synonyms Phenylephrine | (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol | Metasympatol | Mezaton | Phenylephrine Hydrochloride | Phenylephrine Tannate | Tannate, Phenylephrine | Metaoxedrin | Neo-Synephrine | Neo Synephrine | Neosynephrine
Chemical Information
Molecular Formula C9H13NO2
CAS Registry Number 59-42-7
SMILES CNCC(C1=CC(=CC=C1)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rales22.12.01.011---
Respiratory distress22.02.01.012---
Seizure17.12.03.001--
Shock24.06.02.002---
Skin disorder23.03.03.007---
Skin exfoliation23.03.07.003---
Skin necrosis23.03.03.011---
Somnolence17.02.04.006; 19.02.05.003--
Subarachnoid haemorrhage12.01.10.011; 17.08.01.010; 24.07.04.0040.002066%-
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.0070.001377%-
Tension19.06.02.005---
Tremor17.01.06.002--
Urticaria10.01.06.001; 23.04.02.001--
Ventricular arrhythmia02.03.04.006--
Ventricular extrasystoles02.03.04.007---
Vision blurred06.02.06.007; 17.17.01.010--
Vitreous floaters06.09.01.005--
Vomiting07.01.07.003--
Underweight14.03.02.017---
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Angiopathy24.03.02.007---
Cardiac disorder02.11.01.003---
Ischaemia24.04.02.004---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.002---
Urinary tract obstruction20.08.01.004--
Acute kidney injury20.01.03.016--
Sensitisation08.01.05.009; 10.02.01.012---
Posterior reversible encephalopathy syndrome17.13.02.0070.001377%
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages